Caroline Palomeque
Stock Analyst at Maxim Group
(2.59)
# 2,214
Out of 4,761 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $3.17 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $34.56 | +70.72% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $187.86 | -18.02% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $57.75 | +0.43% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $152.43 | +8.90% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $20.73 | +88.13% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $7.27 | +739.06% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $8.35 | +379.04% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.17
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $34.56
Upside: +70.72%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $187.86
Upside: -18.02%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $57.75
Upside: +0.43%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $152.43
Upside: +8.90%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $20.73
Upside: +88.13%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $7.27
Upside: +739.06%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $8.35
Upside: +379.04%